Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2020-02-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details the stock price drop over two trading days exceeding 20%, the company's self-inspection results, confirmation from controlling shareholders, risk warnings, and a board statement confirming no undisclosed material information. The document is short (1368 characters) and serves as a regulatory disclosure about stock price abnormality rather than a financial report or earnings release. It does not contain financial statements or detailed financial data but is a formal announcement to comply with stock exchange rules regarding abnormal stock price movements. Therefore, it fits best under Regulatory Filings (RNS).
2020-02-11 Chinese
哈药集团有限公司关于哈药股份股票交易异常波动问询函的回复
Regulatory Filings Classification · 95% confidence The document is a reply letter from 哈药集团有限公司 regarding an inquiry about abnormal stock price fluctuations over three trading days. It references stock price movements and regulatory rules from the Shanghai Stock Exchange but does not contain financial statements, earnings data, or detailed financial analysis. The document is short (519 characters) and serves as a regulatory response to a market inquiry rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2020-02-06 Chinese
股票交易异常波动暨风险提示公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 哈药集团股份有限公司 regarding abnormal stock price fluctuations over three consecutive trading days, with explanations and risk warnings to investors. It includes details about the stock price deviation, company self-inspection results, risk reminders, and a board statement confirming no undisclosed material information. The document does not contain financial statements or detailed financial data but serves as a risk disclosure and trading abnormality notice. It is not an annual or interim report, earnings release, or any detailed financial report. It fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about stock trading risks and company disclosures.
2020-02-06 Chinese
股票交易风险提示公告
Regulatory Filings Classification · 95% confidence The document is a stock trading risk warning announcement issued by the company's board, highlighting stock price volatility, earnings forecast reduction, and risk reminders to investors. It references prior announcements and provides risk disclosures but does not contain detailed financial statements or comprehensive report data. The document length is short (1087 characters) and serves as a regulatory disclosure to inform investors about trading risks and company status. It is not an annual report, earnings release, or financial supplement. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2020-02-04 Chinese
哈药集团有限公司关于哈药集团股份有限公司股票交易异常波动问询函的回复
Regulatory Filings Classification · 95% confidence The document is a reply to an inquiry about abnormal stock price fluctuations, referencing stock price changes and regulatory rules from the Shanghai Stock Exchange. It does not contain financial statements, management discussion, or detailed financial data. It is a regulatory response to a stock trading inquiry, which fits best under Regulatory Filings (RNS) as it is a compliance-related announcement without substantive financial report content.
2020-02-03 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by 哈药集团股份有限公司. It discusses the stock price movement exceeding 20% over two trading days, the company's self-inspection results, confirmation from controlling shareholders, risk warnings, and a board statement confirming no undisclosed material information. The document is short (1418 characters) and focuses on stock price abnormality and related disclosures, not on financial statements or detailed financial results. It is not an earnings release or annual report but a regulatory announcement about stock price behavior and related risk disclosures. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2020-02-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.